Neurozen Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
6
Neurozen General Information
Description
Developer of a diagnosis technology designed for the early detection of Alzheimer's. The company uses advanced, deep learning-enabled neuroimaging and genetic services for risk assessment and early detection, enabling doctors to treat the disease before irreversible brain damage or cognitive decline has occurred.
Contact Information
Website
www.neurozen.aiCorporate Office
- 5th Floor, 413, Teheran-ro
- Seoul, Gangnam-gu
- South Korea
Corporate Office
- 5th Floor, 413, Teheran-ro
- Seoul, Gangnam-gu
- South Korea
Neurozen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue | |||
| 1. Later Stage VC (Series A) | 29-Jul-2021 | Completed | Generating Revenue |
Neurozen Patents
Neurozen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023068619-A1 | Method for predicting cognitive impairment by using spatiotemporal memory test and brain image information, device for performing same, and computer-readable recording medium | Inactive | 22-Oct-2021 | ||
| WO-2023068732-A1 | Method for acquiring score for neuropsychological test, neuropsychological test apparatus performing same, and computer-readable recording medium | Inactive | 18-Oct-2021 | ||
| WO-2023013959-A1 | Apparatus and method for predicting amyloid beta accumulation | Inactive | 03-Aug-2021 | ||
| WO-2022114526-A1 | Single nucleotide polymorphism marker for predicting risk of alzheimer's disease and use thereof | Inactive | 25-Nov-2020 | C12Q1/6883 |
Neurozen Signals
Neurozen Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Colopl Next | Corporate Venture Capital | Minority | ||
| DT & Investment | Corporate Venture Capital | Minority | ||
| Friend Investment Partners | Venture Capital | Minority | ||
| Friend Investment Partners (Seoul) | Venture Capital | Minority | ||
| i Plus Center | Corporation | Minority |
Neurozen FAQs
-
When was Neurozen founded?
Neurozen was founded in 2015.
-
Where is Neurozen headquartered?
Neurozen is headquartered in Seoul, South Korea.
-
What is the size of Neurozen?
Neurozen has 6 total employees.
-
What industry is Neurozen in?
Neurozen’s primary industry is Diagnostic Equipment.
-
Is Neurozen a private or public company?
Neurozen is a Private company.
-
What is Neurozen’s current revenue?
The current revenue for Neurozen is .
-
Who are Neurozen’s investors?
Colopl Next, DT & Investment, Friend Investment Partners, Friend Investment Partners (Seoul), and i Plus Center are 5 of 6 investors who have invested in Neurozen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process